aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Q32 Bio, founded with the mission to transform the lives of patients with immune diseases, focuses on developing targeted biotherapeutics that rebalance the immune system. The company aims to address severe autoimmune and inflammatory diseases through innovative therapies that target key regulators of both the innate and adaptive immune systems. Their market focus is on providing effective treatments for conditions that currently have limited therapeutic options.
Q32 Bio boasts a team of experienced industry professionals, including scientists, immunologists, and drug developers dedicated to their mission. The company has garnered attention from notable investors and has made significant strides in its research and development efforts. With two promising programs underway, Q32 Bio is making a substantial impact in the field of immunotherapy, offering hope to patients with severe autoimmune conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Biotherapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Q32 Bio founded?
Q32 Bio was founded in 2017.
Where is Q32 Bio's headquarters located?
Q32 Bio's headquarters is located in Cambridge, MA, US.
When was Q32 Bio's last funding round?
Q32 Bio's most recent funding round was for $60M (USD) in October 2020.
How many employees does Q32 Bio have?
Q32 Bio has 44 employees as of Feb 4, 2024.
How much has Q32 Bio raised to-date?
As of July 05, 2023, Q32 Bio has raised a total of $106M (USD) since Oct 29, 2020.
Add Comparison
Total Raised to Date
$106M
USD
Last Update Oct 29, 2020
Last Deal Details
$60M
USD
Oct 29, 2020
Series B
Total Employees Over Time
44
As of Feb 2024
Q32 Bio Address
1 Broadway
Cambridge,
Massachusetts
02142
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts